Receive case studies from Merck Serono, Teva, MHRA, Cinfa Biotech GmbH, Selecta Biosciences, Norwegian Medicines Agency and more | Biosimilars and Biobetters

Share Article

SMi's Biosimilars and Biobetters conference, taking place on the 30th September - 1st October 2015 in London, will address pharmacovigilance of biosimilars, patent litigation, market access, product commercialisation barriers and global market developments. The two-day conference programme will address these developments with an array of case studies from leading biosimilar and regulatory players including Merck Serono, Teva, MHRA, Cinfa Biotech GmbH, Harvest Moon Pharmaceuticals USA Inc, GfK, Selecta Biosciences, Norwegian Medicines Agency and many more.

News Image

SMi's 6th annual Biosimilars and Biobetters conference will provide the ideal platform to engage in scientific discussions and debate the best practices and solutions to improve industry performance through technical case studies and practical advice from leading biosimilar and regulatory players from organisations including Harvest Moon Pharmaceuticals USA Inc, GfK, Selecta Biosciences, Cinfa Biotech GmbH, Norwegian Medicines Agency and more. Unique perspectives will be shared on:
Evolving biosimilar regulatory landscape
Market access and product commercialisation barriers
How advanced structural characterisation techniques can support regulatory approval
How to engage payers and clinicians on safety and adoption of Biosimilars and Biobetters

Speaker Panel includes:
Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc.
Shahin Kauser, Senior Scientific Assessor, MHRA
Chris Teale, Vice President Europe, GfK NOP Ltd
Bracha Timan, Director, Israel Site Head, Global Bioassays & Technology, Global R&D, Teva
Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
Karsten Roth, Director Clinical Operations, Cinfa Biotech GmbH
Alan Sheppard, Principal, Global Generics and Biosimilars, IMS Health
Steinar Madsen, Medical Director, Norwegian Medicines Agency

To view the full speaker line-up and complete conference programme, visit http://www.biosimilars-biobetters.co.uk/prweb

Plus, don't miss the interactive conference workshops:

A: Assessing the Regulatory Framework for Europe and the US – Developing Future Biologics
Led by: Lincoln Tsung, Daniel Kracov, Jennifer Sklenar, Partners, Arnold & Porter (UK) LLP | 29th September 2015, 13.30 - 17.30

B: Biosimilars – Understanding the Regulatory Processes and the Commercial Realities
Led by: Peter Wittner, Senior Consultant, Interpharm Consultancy | 2nd October 2015, 08.30 - 12.30

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sonal Patel
Visit website

Media